These results suggest there is no excess cardiovascular risk with tirzepatide and are consistent with the improvements of numerous surrogate markers of cardiovascular health, including weight reduction, glycemic control with less hypoglycemia, blood pressure reduction, and improvements in the lipid profile
Retatrutide Dosing Schedule (Clinical Trial Protocols) Week Range Weekly Dose Notes on Titration & Tolerability Key Points: Retatrutide is given as a once-weekly subcutaneous injection
Timing exercise relative to the weekly injection is worth considering
Rotating injection sites with each dose helps prevent irritation and lumps under the skin
It is about fostering a healthier way of living by simply eating smart
Published, peer-reviewed, placebo-controlled clinical trial data from some of the most rigorous obesity research ever conducted